Abstract
The safety of insulin and all diabetes treatments in early pregnancy, particularly during the first 40 days after conception, is paramount.1,2 However, few insulin (or diabetes device) manufacturers rigorously evaluate newer diabetes treatments before and during pregnancy. In The Lancet Diabetes & Endocrinology Elisabeth R Mathiesen and colleagues3 performed a non-inferiority trial to compare the efficacy and safety of insulin degludec with insulin detemir in combination with insulin aspart, in pregnant women with type 1 diabetes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
